Mechanistically, we show that targeting MALAT1 induces DSBs and apoptosis, which makes prostate cancer cells vulnerable to DNA repair inhibitors, such as olaparib, and DNA-damaging agents like doxorubicin. This evidence concerns the gene MALAT1 and Familial prostate cancer.